ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 1229 • ACR Convergence 2023

    Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus

    Tala El Tal1, justine ledochowski2, Sarah Mossad3, Victoria Lishak3, Ibrahim Mohamed4, Joanna Law3, Lawrence Ng3, Paris Moaf3, Asha Jeyanathan3, Adrienne Davis3, Linda Hiraki3, Deborah Levy3, Zahi Touma5, Natoshia Cunningham6, Ashley Danguecan3 and Andrea Knight3, 1Division of Rheumatology, The Hospital for Sick Children, andDivision of Rheumatology, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, 2Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4The Hospital for Sick Children, Brampton, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Michigan State University, Grand Rapids, MI

    Background/Purpose: Cognitive dysfunction (including executive dysfunction) affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), with potential adverse effects on health-related quality…
  • Abstract Number: 2452 • ACR Convergence 2023

    Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System

    Rachel Robbins1, Toni Rush2 and Jess Edison3, 1Walter Reed National Military Medical Center, Germantown, MD, 2Health Research Tx, Pace, FL, 3Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD

    Background/Purpose: While generally believed to be a safe, well-established treatment, hydroxychloroquine (HCQ) use is associated with irreversible retinal toxicity requiring regular monitoring. The objective of…
  • Abstract Number: 1243 • ACR Convergence 2023

    Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

    Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL

    Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
  • Abstract Number: 2510 • ACR Convergence 2023

    Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

    Tineke van Wesemael1, Jessica Borgers2, Kyra Gelderman3, Els Verdegaal4, C.M. Korse5, M.J.P. Welters6, Ellen Kapiteijn7, W.J. van Houdt2, Sjoerd van der Burg6, René Toes1, J.V. Thienen2, John Haanen2 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, 3Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Amsterdam, Netherlands, 5Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, Netherlands, 6Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands, 7Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: PD-1 immune checkpoint inhibitors are able to re-activate restrained anti-tumor T-cell responses in melanoma patients. However, PD-1 inhibition may also activate auto-reactive T-cells leading…
  • Abstract Number: 1295 • ACR Convergence 2023

    Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort

    Charis Meng1, Yvonne Lee2, Orit Schieir3, Marie-France Valois4, Margaret Butler1, Gilles Boire5, Glen Hazelwood6, Carol Hitchon7, Edward Keystone8, Diane Tin9, Carter Thorne10, Louis Bessette11, Janet Pope12, Susan Bartlett13 and Vivian Bykerk1, 1Hospital for Special Surgery, New York, NY, 2Northwestern University, Chicago, IL, 3McGill University, Montréal, QC, Canada, 4McGill University, Pointe-Claire, QC, Canada, 5Université de Sherbrooke, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Manitoba, MB, Canada, 8Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 9Centre of Arthritis Excellence, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, 12University of Western Ontario, London, ON, Canada, 13McGill University, Montreal, QC, Canada

    Background/Purpose: Early RA patients may present with more tender than swollen joints, which can persist during DMARD therapy. Elevated TSJD (tender-swollen joint difference) is often…
  • Abstract Number: 2517 • ACR Convergence 2023

    The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

    Erdem Bektas1, Rabia Deniz2, Zeliha Emrence3, Sema Sırma Ekmekci3, Neslihan Abacı3, Shirkhan Amikishiyev4, Yasemin Yalçınkaya4, Bahar Artim Esen4, Murat Inanç5 and Ahmet Gul6, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 2University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, 3Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
  • Abstract Number: 1303 • ACR Convergence 2023

    Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis

    Audrey-Anne Couture1, Nathalie Carrier2, Hugues Allard-Chamard3, Sophie ROUX3, Patrick Liang3 and Gilles Boire3, 1University of Montréal, Montréal, QC, Canada, 2CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, 3Université de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
  • Abstract Number: 2587 • ACR Convergence 2023

    Measuring Frailty in SLE: Agreement Among Methods

    Patti Katz1, Maria Dall'Era2, Kamil Barbour3, Kurt Greenlund3, Cristina Lanata4, Caroline Gordon5, Lindsey Criswell6 and Jinoos Yazdany7, 1University of California San Francisco, San Rafael, CA, 2University of California San Francisco, San Francisco, CA, 3Centers for Disease Control and Prevention, Atlanta, GA, 4National Human Genome Research Institute, Washington, DC, 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 6NIH/NHGRI, Bethesda, MD, 7University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA

    Background/Purpose: Frailty, conceptualized as an accumulation of deficits across multiple physiological systems, was first examined in SLE in 2017 using the Fried Frailty Phenotype criteria…
  • Abstract Number: 1472 • ACR Convergence 2023

    Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience

    Asif Hitawala1, Zerai Manna2, Yenealem Temesgen-Oyelakin3, Elaine Poncio3, Christopher Koh4, sarfaraz Hasni2 and Theo Heller4, 1NIDDK/NIH, Bethesda, MD, 2Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4NIDDK/Liver disease branch, Bethesda, MD

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are known to have hepatic injury (HI), however large-scale longitudinal studies are lacking.We report our experience of HI…
  • Abstract Number: 1488 • ACR Convergence 2023

    Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus

    Patti Katz1, Sofia Pedro2, Jiyoon Choi3 and Kaleb Michaud4, 1University of California San Francisco, San Rafael, CA, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Bristol Myers Squibb, Lawrenceville, NJ, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for SLE. While GCs do provide benefit, there are potential side effects that increase with…
  • Abstract Number: 1604 • ACR Convergence 2023

    First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Jonathan Thaler1, Yasaman Ahmadzadeh2, Danieli Andrade3, leslie skeith4, Maria Tektonidou5, Savino Sciascia6, Vittorio Pengo7, Jose Pardos-Gea8, Guillermo Ruiz-Irastorza9, Chary Lopez-Pedrera10, H Michael Belmont11, Kello Nina12, Paul R. Fortin13, Denis WAHL14, Maria Gerosa15, Guilherme De Jesús16, Zhuoli Zhang17, Tatsuya Atsuma18, Maria Efthymiou19, D. Ware Branch20, Laura Andreoli21, Esther Rodriguez almaraz22, Michelle Petri23, Giulia Pazzola24, Ricard Cervera25, Bahar Artim Esen26, Hui Shi27, Jason Knight27, Guillermo Pons-Estel28, Rohan Willis29, Ali Duarte-Garcia30, Maria Laura Bertolaccini31, Hannah Cohen32, Doruk Erkan1 and On Behalf Of APS ACTION33, 1Hospital for Special Surgery, New York, NY, 2Roger Williams Medical Center, Providence, RI, 3University of São Paulo, São Paulo, Brazil, 4University of Calgary, Calgary, AB, Canada, 5Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 6University of Turin, Torino, Italy, 7Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 8Vall d'Hebron University Hospital, Barcelona, Spain, 9Hospital Universitario Cruces, Barakaldo, Spain, 10IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 11NYU School of Medicine, New York, NY, 12Northwell Health, Brooklyn, NY, 13Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 14University of Lorraine, Nancy, France, 15University of Milan, Milano, Italy, 16Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 17Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 18Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 19University College London, London, United Kingdom, 20University of Utah, Salt Lake City, UT, 21University of Brescia, Brescia, Italy, 22Hospital Universitario 12 de Octubre, Madrid, Spain, 23Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 24Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, 25Hospital Clínic de Barcelona, Barcelona, Spain, 26Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 27University of Michigan, Ann Arbor, MI, 28CREAR, Rosario, Argentina, 29University of Texas Medical Branch, Galveston, TX, 30Mayo Clinic, Rochester, MN, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom, 33on behalf of APS ACTION, New York, NY

    Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • Abstract Number: 0937 • ACR Convergence 2022

    Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response

    Emanuele Bozzalla Cassione1, Iolanda Mazzucchelli2, Terenzj Luvaro2, Blerina Xoxi2, Ludovico De Stefano2, Garifallia Sakellariou2, Silvia Grignaschi2, Mehrad Mansoubi2, Serena Bugatti2, Carlomaurizio Montecucco2 and Antonio Manzo3, 1University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, 2University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, 3IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy

    Background/Purpose: Drug-free (DF) remission, as a putative proxy of cure, has recently gained the attention of the scientific community as a desirable new target of…
  • Abstract Number: 2116 • ACR Convergence 2022

    Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis

    Juan Josè de Agustin1, Gustavo Añez1, delia reina2, Sergi Heredia3, Felipe Julio Ramirez Garcia4, Andrea Cuervo5, Jesus Rodriguez6, Carmen Moragues6, Patricia Moya7, Mireia Moreno8, Marta Arévalo8, Manel Pujol9, Georgina Salvador9, Noemi Busquets10, andres Ponce10, Ana Maria Laiz Alonso7 and MAria Pascual Pastor11, 1Vall D'hebron University Hospital, Barcelona, Spain, 2Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, 3Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, 4Hospital Clínic, Barcelona, Spain, 5Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, 6Hospital Bellvitge, Hospitalet de Llobregat, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 9Hospital Universitario MútuaTerrassa, Terrassa, Spain, 10Hospital General de Granollers, Granollers, Spain, 11Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
  • Abstract Number: 1389 • ACR Convergence 2022

    The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors

    Patrick Garnero1, Evelyne Gineyts1, Jean-Charles Rousseau1, Pascal Richette2, Jérémie SELLAM3 and Roland Chapurlat1, 1INSERM 1033, Lyon, France, 2Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France

    Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology